Article
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.
Scientific reports - 23 Nov 2017
Huang Sung-Hsi, Lin Shu-Wen, Chang Sui-Yuan, Lin Ya-Ting, Chiang Chieh, Hsiao Chin-Fu, Sun Hsin-Yun, Liu Wen-Chun, Su Yi-Ching, Hung Chien-Ching, Chang Shan-Chwen
Abstract excerpt
We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456 HIV-positive patients who had received 2 nucleos(t)ide reverse-transcriptase inhibitors plus efavirenz (600 mg daily) for 2 weeks or longer and had their CYP2B6 516G>T polymorphism and efavirenz C12 determined. The median efavirenz C12 was 2.41 mg/L (IQR, 1.93-3.14). In analysis of covariance models, patients with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.